Atlas Trials

Chemotherapy Combined With Bevacizumab Neoadjuvant Therapy for HER2-negative Breast Cancer

Clinical trial NCT05525767 · RECRUITING

Trial details

NCT number
NCT05525767
Sponsor
Hebei Medical University Fourth Hospital
Status
RECRUITING
Phase
Phase 4
Study type
INTERVENTIONAL
Solid Tumor
Start date
2022-03-31
Primary completion
2026-10-31
Enrollment
75

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.